- Raised funding round, Jun 2019
- Raised funding round, May 2017
About
MabTrix is a preclinical-stage biopharmaceutical company developing a function-blocking therapeutic monoclonal antibody (MAb) for inflammatory bowel disease (IBD) or an orphan form as initial indication. MabTrix aims to develop a novel humanized MAb that specifically inhibits the enzymatic activity of matrix metalloprotease (MMP) 9 by binding to the catalytic site of the activated enzyme. The unique targeting of the MAb for the catalytic site was enabled by immunization using a novel proprietary molecule derived from the catalytic domain, designated Zn-tripod. MMP-9 has been implicated in various inflammatory and malignant diseases. Preclinical studies suggest that interference with MMP-9 activity may lead to reduced inflammation or tumor load in IBD or cancer patients respectively. MAbs generated using the novel immunization technology, designated metallobodies, show promising efficacy in IBD and other disease models. The company's technology was developed in and licensed from the laboratory of Professor Irit Sagi at the Weizmann Institute of Science in Israel. MabTrix was established in the FutuRx incubator and Yeda Research and Development Company Ltd.
Funding history · 2 rounds · — total
Q&A
- What is MabTrix's primary focus?
- MabTrix is a preclinical-stage biopharmaceutical company developing a function-blocking therapeutic monoclonal antibody (MAb) for inflammatory bowel disease (IBD) or an orphan form as an initial indication.
- What is the status of MabTrix?
- MabTrix is currently inactive, having ceased operations in December 2020.
- When was MabTrix founded?
- MabTrix was founded in December 2015.
- Which organizations were involved in the establishment of MabTrix?
- MabTrix was established in the FutuRx incubator and Yeda Research and Development Company Ltd.
- From where was MabTrix's core technology licensed?
- MabTrix's technology was developed in and licensed from the laboratory of Professor Irit Sagi at the Weizmann Institute of Science in Israel.
- When did MabTrix receive its last known funding?
- MabTrix received funding in June 2019 from RMGP Biopharma Investment Fund.
- What is the primary sector of MabTrix?
- MabTrix operates in the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2015-12 |
|---|---|
| Employees (exact) | 6 |
| Status reason | Non Active, Dec 2020 ceased to operate |